awmsg logo



eltrombopag (Revolade®)


Reference No. 2692

Publication date:
21/10/2016


Appraisal information

eltrombopag (Revolade®) 25 mg film-coated tablet
eltrombopag (Revolade®) 50 mg film-coated tablet
eltrombopag (Revolade®) 25 mg powder for oral suspension


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 07/09/2016
AWMSG meeting date: 12/10/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2916
Ministerial ratification: 20/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Eltrombopag (Revolade®) is recommended as an option for use within NHS Wales for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download